Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 11/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11401106 | 0.73 | MAPK1 (0.42) | PDK2CYP2D6MAPK1THRBTDP1 | |
| SCHEMBL7819239 | 0.72 | MAPK1 (0.49) | SLC6A4SLC6A3PDK2KDM4EMAPK1 | |
| SCHEMBL20833211 | 0.72 | KDM1A (0.41) | SLC6A4SLC6A3MAPK1 | |
| SCHEMBL20833501 | 0.72 | KDM1A (0.41) | SLC6A4SLC6A3MAPK1 | |
| SCHEMBL20833495 | 0.72 | KDM1A (0.41) | SLC6A4SLC6A3MAPK1 | |
| SCHEMBL7312265 | 0.72 | PDK2 (0.45) | PDK2MAPK1THRBTDP1KMT2A | |
| SCHEMBL20833281 | 0.71 | SLC6A4 (0.40) | SLC6A4SLC6A3KDM4ENPC1CYP1A2 | |
| SCHEMBL20833048 | 0.71 | SLC6A4 (0.40) | SLC6A4SLC6A3KDM4ENPC1CYP1A2 | |
| SCHEMBL20031068 | 0.70 | TMEM97 (0.38) | SLC6A4SLC6A3KDM4ENPC1CYP1A2 | |
| Hydrochloric Acid SCHEMBL31706813 | 0.70 | SLC6A4 (0.39) | SLC6A4SLC6A3KDM4ENPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| WO-2020191252-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | WO | disclosed |
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-07-23 | — | — | US | disclosed |
| WO-2019055951-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | SLC6A4 1561/4885SLC6A3 3086/4885PDK2 3445/4885 |
| US-20200231620-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | SLC6A4 2946/4885SLC6A3 3986/4885PDK2 4378/4885 |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | SLC6A4 2946/4885SLC6A3 3986/4885PDK2 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.